ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
failure to respond or late response
on 24 May 2024
Last Applicant/ Owned by
455 Mission Bay Boulevard South
San Francisco
CA
94158
Serial Number
97527017 filed on 29th Jul 2022
Registration Number
N/A
Correspondent Address
San Francisco, CA 94158
UNITED STATES
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
THE WORLD'S FIRST UNIVERSAL GENE THERAPY
Testing, inspection, research, or development of pharmaceutical preparations for gene therapy Anti-cancer preparations; Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Testing, inspection, research, or development of pharmaceutical preparations for gene therapy
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Anti-cancer preparations; Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 97527017
Mark Type
No Service Mark
Attorney Docket Number
No
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 24th May 2024 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| 24th May 2024 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| 08th Feb 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| 08th Feb 2024 | NON-FINAL ACTION E-MAILED |
| 08th Feb 2024 | NON-FINAL ACTION WRITTEN |
| 25th Jan 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 25th Jan 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 25th Jan 2024 | ASSIGNED TO LIE |
| 06th Sep 2023 | NOTICE OF REVIVAL - E-MAILED |
| 06th Sep 2023 | PETITION TO REVIVE-GRANTED |